Literature DB >> 1589760

Gaucher disease: new molecular approaches to diagnosis and treatment.

E Beutler1.   

Abstract

Gaucher disease is characterized by the accumulation of glucocerebroside, leading to enlargement of the liver and spleen and lesions in the bones. It is caused by an inherited deficiency of the enzyme glucocerebrosidase. Many mutations exist, but four of these account for over 97% of the mutations in Ashkenazi Jews, the population group in which Gaucher disease is the most common. Although there is a strong relation between the mutations and disease manifestations, genetic counseling is made difficult by the fact that within each genotype there is considerable variability in the severity of the disease. Intravenous infusion of glucocerebrosidase is an effective treatment, but the availability of enzyme replacement therapy is limited by its high cost. Marrow transplantation is also effective in treating the disease, but is rarely performed because of the risks involved. In the future gene transfer may become the treatment of choice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1589760     DOI: 10.1126/science.1589760

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  55 in total

1.  Quality of life assessment in adults with type 1 Gaucher disease.

Authors:  B J Masek; K B Sims; C M Bove; M S Korson; P Short; D K Norman
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

2.  Mutation analysis in 46 British and Irish patients with Gaucher's disease.

Authors:  C E Hatton; A Cooper; C Whitehouse; J E Wraith
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

3.  Alglucerase for Gaucher's disease: dose, costs and benefits.

Authors:  E Beutler; A M Garber
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

Review 4.  The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Authors:  Arash Velayati; W Haung Yu; Ellen Sidransky
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

Review 5.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

6.  Human chitotriosidase polymorphisms G354R and A442V associated with reduced enzyme activity.

Authors:  Pauline Lee; Jill Waalen; Karen Crain; Aaron Smargon; Ernest Beutler
Journal:  Blood Cells Mol Dis       Date:  2007-08-10       Impact factor: 3.039

7.  Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy.

Authors:  Reena V Kartha; James Joers; Marcia R Terluk; Abigail Travis; Kyle Rudser; Paul J Tuite; Neal J Weinreb; Jeanine R Jarnes; James C Cloyd; Gülin Öz
Journal:  J Inherit Metab Dis       Date:  2019-12-17       Impact factor: 4.982

8.  Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.

Authors:  J J MacKenzie; D Amato; J T Clarke
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

9.  Long-term in vivo expression of the human glucocerebrosidase gene in nonhuman primates after CD34+ hematopoietic cell transduction with cell-free retroviral vector preparations.

Authors:  L C Xu; S Karlsson; E R Byrne; S Kluepfel-Stahl; S W Kessler; B A Agricola; S Sellers; M Kirby; C E Dunbar; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

Review 10.  Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease.

Authors:  Caleb Pitcairn; Willayat Yousuf Wani; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2018-03-14       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.